InfiCure Bio has developed a new and unique preclinical mouse model, the NIF mouse, which spontaneously develops kidney fibrosis, liver fibrosis and chronic liver inflammation.
We offer expert led, tailored, high-quality drug validation services for R&D companies and CRO’s.
Our unique NIF mouse offers extraordinary research advantages including the possibility to study effects on both liver and kidneys in the same mouse and to distinguish between metabolic and anti-inflammatory/anti-fibrotic actions of tested substances.
The pathological progress in the NIF mouse is similar to many human conditions and the spontaneous development makes it possible for us to save time by shortening test protocols. InfiCure Bio is ready to break the status quo in anti-fibrotic drug development.